Table 1 Baseline characteristics stratified by the presence or absence of ACLF at enrollment (derivation cohort).

From: The role of RIPK1 mediated cell death in acute on chronic liver failure

 

No ACLF (n = 187)

ACLF (n = 124)

p values

Age (years)

58 (50–67)

56 (49–64)

0.167

Male (n, %)

129 (69.4)

85 (68)

0.804

Etiology (n, %)

 Alcohol

86 (45.9)

70 (56.5)

0.011

 Alcohol + HCV

64 (34.2)

55 (44.4)

0.339

 HCV

50 (26.7)

25 (20.2)

0.316

 Non-alcoholic steatohepatitis

11 (5.9)

6 (4.8)

0.803

 Other

14 (7.5)

7 (5.6)

0.647

Active alcoholism at enrollment (n, %)

17 (9.1)

29 (23.4)

0.003

Ascites (n, %)

61 (32.6)

83 (66.9)

0.066

Gastrointestinal bleeding (n, %)

22 (11.8)

14 (14.3)

>0.999

Bacterial infection (n, %)

19 (32.2)

15 (31.9)

>0.999

Organ failure (n, %)

 Liver

14 (7.5)

47 (37.9)

<0.001

 Kidney

-

77 (62.1)

-

 Brain

7 (3.7)

26 (20.9)

<0.001

 Coagulation

4 (2.1)

27 (21.8)

<0.001

 Cardiac

1 (0.5)

19 (15.3)

<0.001

 Respiratory

1 (0.5)

10 (8)

0.001

Laboratory values

 White blood cell (× 109/L)

5.6 (4.1–8.9)

9 (5.8–13.8)

<0.001

 Bilirubin (mg/dL)

2.7 (1.5–4.9)

6 (1.9–16.8)

<0.001

 Prothrombin time (international normalized ratio)

1.5 (1.3–1.8)

1.7 (1.4–2.3)

<0.001

 Albumin (g/dL)

2.8 ± 0.7

2.9 ± 0.7

0.608

 Creatinine (mg/dL)

1 (0.8-1.3)

2.2 (0.9–3.2)

<0.001

 Sodium (mmol/L)

137 (132–140)

134 (130–139)

0.004

 Platelets (109/L)

86.6 (56.5–127.5)

77 (51–126)

0.359

Scores

 MELD

16 (13–21)

26 (21–32.5)

<0.001

 MELD Na

18 (14–23)

29 (23–34)

<0.001

 Child-Pugh score

9 (8–11)

11 (9–12.5)

<0.001

 CLIF-OFs

7 (6–8)

10 (9–11)

<0.001

Outcome

 28-day mortality (n, %)

9 (5.9)

22 (22.4)

<0.001

 90-day mortality (n, %)

22 (14.4)

35 (35.7)

<0.001

  1. Continues data are expressed as mean ± standard deviation or median (Q1–Q3), as appropriate. Categorical data are expressed as n (%)
  2. ACLF acute on chronic liver failure, CLIF-OFs chronic liver failure-organ failure score, HCV hepatitis C virus, MELD model for end-stage liver disease.